COMPANIES COVERED
Astrazeneca Plc.Download FREE Report Sample
Download Free sampleMale hypogonadism?is a condition in which the body doesn't produce enough of the hormone that plays a key role in?masculine?growth and development during puberty (testosterone) or enough sperm or both. You can be born with?male hypogonadism, or it can develop later in life, often from injury or infection.
Male Hypogonadism Market contains market size and forecasts of Male Hypogonadism in Global, including the following market information:
Global Male Hypogonadism Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Male Hypogonadism market was valued at 3128.6 million in 2021 and is projected to reach US$ 3691.7 million by 2028, at a CAGR of 2.4% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Testosterone Replacement Therapy Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Male Hypogonadism include Astrazeneca Plc., Merck & Co. Inc., Laboratories Genevrier, Allergan Plc., Endo International Plc., Ferring, AbbVie Inc., Eli Lilly and Company Ltd. and Finox Biotech, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Male Hypogonadism companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Male Hypogonadism Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Male Hypogonadism Market Segment Percentages, by Type, 2021 (%)
Testosterone Replacement Therapy
Gonadotropin-Releasing Hormones Therapy
Global Male Hypogonadism Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Male Hypogonadism Market Segment Percentages, by Application, 2021 (%)
Kallmann Syndrome
Klinefelters Syndrome
Pituitary Disorders
Others
Global Male Hypogonadism Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Male Hypogonadism Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Male Hypogonadism revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Male Hypogonadism revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Astrazeneca Plc.
Merck & Co. Inc.
Laboratories Genevrier
Allergan Plc.
Endo International Plc.
Ferring
AbbVie Inc.
Eli Lilly and Company Ltd.
Finox Biotech
Teva Pharmaceutical Industries Ltd.
Bayer AG
IBSA Institut Biochimque
Speak to our Custom Research Team and get the Custom Research in a budget
Custom ResearchFrequently Asked Questions ?
A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.
A license granted to multiple users.
A license granted to a single business site/establishment.
A license granted to all employees within organisation access to the product.
Upto Working 24 to 48 hrs
Upto 72 hrs max - Weekends and Public Holidays
Online Payments with PayPal and CCavenue
Wire Transfer/Bank Transfer
Hard Copy
Industry Market SizeSWOT AnalysisIndustry Major PlayersRevenue ForecastsHistorical and Forecast GrowthProfitability Analysis
